Articles in the Category ”Products”

NEW! We’re Launching ImpaRATOR™!

We are excited to launch ImpaRATOR, an O-glycan-dependent protease that digests proteins carrying mucin-type O-glycans, including sialylated species, N-terminally of glycosylated Ser and Thr residues!
The enzyme generates glycopeptides carrying O-glycans, which enables O-glycan profiling, site occupancy determination and O-glycopeptide mapping as well as middle-level approaches using LC-MS analysis.
Read more »

NEW! We’re Launching IgMBRAZOR™!

IgMBRAZOR is a unique IgM-specific protease that digests human IgM at one specific site below the CH2 domain in the heavy chain, generating homogeneous F(ab’)2 and Fc fragments. We’re excited to launch this unique tool today that enables middle-level analysis of the complex and high molecular weight human IgM!
IgMBRAZOR facilitates IgM characterization during, for example, the development of vaccines, therapeutics, and diagnostics. The digestion is complete within 30 minutes, and due to the specificity of the enzyme, there is no risk of overdigestion if the incubation time is prolonged.
Read more »

NEW! We’re Launching GlySERIAS Immobilized

February 20, 2023 | News, Products |

GlySERIAS is a unique enzyme that digests flexible glycine-rich fusion protein linkers such as Gly4Ser and GlyxSery (GS), and polyglycine (G) linkers. Today, we’re happy and proud to be launching this unique SmartEnzyme in a new format – GlySERIAS Immobilized – for digestion of flexible linkers in easy-to-use spin columns!
The enzyme enables separation of the individual domains of multi-functional fusion proteins to facilitate characterization and increase the understanding of these molecules. Middle-level analysis of fusion proteins serves to both reduce the overall sample complexity and allow for domain-specific identification and monitoring of post-translational modifications.
For improved linker removal, we recommend GlySERIAS Immobilized.
For linker characterization, we recommend GlySERIAS Lyophilized.
Read more »

Antibody LC-MS Analysis Service from Genovis!

October 22, 2022 | New Product, News, Products |

We offer fast and accurate LC-MS profiling of human IgG using unique sample preparation based on SmartEnzymes workflows. Our SmartEnzymes enable middle-level LC-MS analysis of antibodies to characterize critical quality attributes such as the glycosylation profile and mass confirmation.
Read more »

FabRICATOR® in Correlative N-glycan Analysis of Cetuximab Produced in Different Expression Systems

A strategy for comparative characterization of cetuximab produced in a variety of expression cell lines is described in this paper from scientists at the National Institute for Bioprocessing Research and Training (NIBRT) in Dublin, Ireland. FabRICATOR (IdeS) is a critical tool in this study, allowing for site-specific glycan analysis to be performed following antibody digestion into F(ab’)2 and Fc/2 subunits.
Read more »

The Click Chemistry used in GlyCLICK® is Awarded the Nobel Prize!

October 6, 2022 | News, Products |

Every autumn, the Royal Swedish Academy of Sciences announces the winners of the prestigious Nobel Prize. This year’s Chemistry Prize goes to Carolyn Bertozzi, Barry Sharpless and Morten Meldal for the development of click chemistry and bioorthogonal chemistry. Click chemistry is a fundamental part of our GlyCLICK technology. By combining Fc glycan remodeling and the award-winning click chemistry, GlyCLICK enables site-specific labeling of antibodies!
Read more »

FabRICATOR® in Middle-Up Quantitative N-Glycan Profiling of Therapeutic Monoclonal Antibodies

A middle-level approach to glycan characterisation is described in this paper by scientists at the University of Geneva and collaborators. FabRICATOR (IdeS), a critical tool in this study, is used to generate Fd’, LC and the glycan-containing Fc subunits, which can be chromatographically separated using HILIC and characterised using mass spectrometry.
Read more »

SmartEnzymes™ for Gene Therapy

May 11, 2022 | News, Products |

The development of advanced gene therapies is promising and gives thousands of patients new hope for a curative treatment. However, many of the current gene therapies are using adeno-associated viruses as transporters of new genetic material. Up to 60% of patients may have antibodies against this viral vehicle and this is usually an exclusion criteria for being eligible for gene therapy. To overcome the presence of neutralizing antibodies, a new strategy includes the use of highly specific IgG proteases to digest the antibody population and increase the uptake of the new genetic material.
Read more »

GlycINATOR® in Peptide Mapping of Fc Domain-Drug Conjugates

The field of antibody-drug conjugates (ADCs) is rapidly emerging as a new, important class of cancer therapeutics. ADCs consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs, and after selective surface receptor binding on cancer cells, the drug is delivered into the intracellular compartment and can exert its cytotoxic effect.
Read more »

GingisREX® in a Bottom-Up Analysis of Histones

Bottom-up mass spectrometry where the intact protein is digested into smaller peptides is an indispensable tool for proteomics and the studying of histone codes. Since histones are enriched with the basic amino acids arginine and lysine, enzymatic digestion is often challenging as peptides too short for LC retention and PTM localization are generated. In addition, the complex workflow entails that the combination of samples preparation, data acquisition and analysis provides a different image of the histone code.


Read more »